What Is Nephrogenic Adenoma? A Benign Bladder Lesion

Nephrogenic adenoma is a benign growth that forms in the lining of the urinary tract, most often the bladder, as a reaction to injury, infection, or chronic irritation. Despite its name containing “adenoma,” the lesion has no malignant potential of its own, though it can look disturbingly similar to cancer under a microscope or on imaging. That resemblance is what makes it clinically important and why understanding the condition matters for anyone who has been diagnosed with one or is undergoing surveillance after treatment.

Where Nephrogenic Adenoma Comes From

For decades the assumption was that nephrogenic adenoma arose from the bladder’s own lining transforming in response to chronic inflammation. The modern understanding is more surprising. A landmark study examined nephrogenic adenomas in kidney transplant recipients and found that the lesion’s cells carried the sex chromosomes of the organ donor, not the recipient. In female patients who received kidneys from male donors, the nephrogenic adenoma tissue was genetically male, while the surrounding bladder tissue was genetically female. The cells also expressed proteins characteristic of kidney tubular cells, including aquaporin 1 and PAX2.¹ In other words, renal tubular cells shed from the kidneys, travel down the urinary tract, and implant themselves in areas of damaged or inflamed bladder lining.²

This origin story explains why the tissue looks so much like kidney tubules when examined under a microscope. The cells are, in a real sense, kidney cells living in the wrong neighborhood. They arrange themselves into small tubular structures that closely mimic the architecture of the kidney’s collecting system, which is exactly what leads to diagnostic confusion with more serious conditions.

Risk Factors and Who Gets It

Nephrogenic adenoma is uncommon, and certain groups are far more likely to develop it. Anything that chronically irritates the bladder lining raises the risk. In a single-institution study of 60 patients, about a quarter had a history of catheter use, and nearly a third had a history of recurrent urinary tract infections. Roughly 42% had a prior history of bladder cancer, and about 27% had undergone intravesical therapy with agents like Bacillus Calmette-Guérin (BCG) or mitomycin C, both of which are used to treat superficial bladder cancers but themselves cause significant bladder inflammation.³

Kidney transplant recipients represent another well-documented at-risk group, which fits neatly with the donor-cell origin theory. Other associations include bladder stones, prior pelvic surgery, and any condition that keeps the bladder chronically inflamed or traumatized. The common thread is mucosal injury: the bladder lining needs to be damaged for those shed renal tubular cells to take hold.

Symptoms and Where the Lesion Appears

Most people with nephrogenic adenoma do have symptoms, though a meaningful minority are found incidentally during evaluation for something else. In one series, about 72% of patients were symptomatic. The most frequent complaint was blood in the urine, present in roughly 41% of cases. Lower urinary tract symptoms like urgency, frequency, or difficulty emptying accounted for about 28%. Smaller numbers presented with pelvic or flank pain, hydronephrosis (blockage of urine drainage from the kidney), or urinary incontinence.⁴

The bladder is by far the most common location. In one six-year institutional review, 14 of 18 cases were in the bladder, with the remainder scattered among the renal pelvis, ureter, and urethra.⁵ Within the bladder, lesions tend to cluster around areas of prior surgery or catheter trauma, particularly the trigone and bladder neck, which are the regions most subject to mechanical irritation.

What It Looks Like Under the Microscope

When a pathologist examines a biopsy of nephrogenic adenoma, the hallmark is small hollow tubules lined by a single layer of flat-to-cuboidal cells. These cells have a distinctive “hobnail” appearance, meaning the nuclei bulge into the tubule lumen. The cytoplasm is usually clear or pink-tinged, and the nuclei are small and bland-looking without prominent nucleoli. A thickened basement membrane often surrounds the tubules, and the surrounding tissue typically shows signs of chronic inflammation with plasma cells and lymphocytes.²

None of these features by themselves are unique, which is part of the diagnostic challenge. Immunohistochemistry, a technique where antibodies are used to detect specific proteins in tissue, helps pathologists confirm the diagnosis. Nephrogenic adenomas stain positive for PAX2 and PAX8, both kidney-lineage markers, and they often express a protein called AMACR (also known as P504S). In one case report, the lesion stained positive for both AMACR/P504S and PAX8, weakly positive for PAX2, and negative for p63 and GATA3.⁶ A larger study found that AMACR was expressed in 56% of cases and high-molecular-weight cytokeratin (CK903) in 97%, while p63 positivity was rare.⁷

The negativity for p63 and GATA3 is particularly useful because both of those markers are typically positive in urothelial carcinoma. A bladder lesion that is PAX2/PAX8 positive and GATA3/p63 negative points strongly toward nephrogenic adenoma rather than cancer.

Why It Gets Confused With Cancer

Nephrogenic adenoma’s clinical significance lies almost entirely in the fact that it mimics malignancy. On cystoscopy, it can appear as a papillary or polypoid mass indistinguishable from a bladder tumor. On CT imaging, its appearance can be similar to that of bladder carcinoma.⁸ And under the microscope, depending on the morphologic pattern, it can be mistaken for prostatic adenocarcinoma, urothelial carcinoma, or clear cell adenocarcinoma.⁹

The most dangerous lookalike is clear cell adenocarcinoma, a rare but aggressive cancer that can share nephrogenic adenoma’s tubular architecture and hobnail cell morphology. A histopathologic comparison found that the two can usually be separated by looking at several features together. Clear cell adenocarcinomas tend to have many more clear cells (the feature the cancer is named for), more severe cellular atypia, much higher rates of cell division, and areas of necrosis. None of the nephrogenic adenomas in one comparative study showed necrosis, while four of five clear cell adenocarcinomas did. The proliferation marker MIB-1 averaged about 5.5 positive cells per 200 in nephrogenic adenomas versus 47 per 200 in clear cell adenocarcinomas. Perhaps most distinctively, strong p53 staining was present in every clear cell adenocarcinoma and none of the nephrogenic adenomas.¹⁰

The difficulty increases when clear cell adenocarcinoma diffusely mimics the pattern of nephrogenic adenoma. In those cases, PAX2 expression can help: it was found in about 89% of nephrogenic adenomas compared to roughly 29–32% of clear cell adenocarcinomas. Features that should raise suspicion for cancer even in a lesion that otherwise resembles nephrogenic adenoma include prominent nuclear enlargement with dark chromatin, invasion into the muscular wall of the bladder, and a high Ki-67 proliferation rate (ranging from 10% to 80% in clear cell adenocarcinomas, versus 0–5% in nephrogenic adenoma).¹¹

A less common but documented morphologic variant of nephrogenic adenoma has a fibromyxoid stroma, meaning the tissue around the tubules has a mucin-rich, gelatinous quality. This particular pattern can be confused with mucinous adenocarcinoma. The distinction again relies on immunohistochemistry: the epithelial component of these fibromyxoid lesions stains positive for pancytokeratin and AMACR, with variable PAX-2 labeling, and is negative for prostate-specific antigen.¹²

Treatment and When Surgery Is Needed

Because nephrogenic adenoma is benign, treatment is generally conservative. The standard approach when a lesion is found during cystoscopy is transurethral resection, essentially shaving or scooping out the growth through a scope inserted into the bladder. This serves a dual purpose: it removes the lesion and provides tissue for the pathologist to confirm the diagnosis and rule out anything more worrisome.

In select cases, the lesion may resolve on its own when the underlying cause of inflammation is addressed. An early case report documented a marked and sustained reduction in a nephrogenic adenoma after the immunosuppressive drug azathioprine was stopped in a kidney transplant recipient, with cytomegalovirus infection identified as a contributing inflammatory trigger.¹³ Similarly, in patients with long-term kidney failure who had been on dialysis with nonfunctioning bladders, nephrogenic metaplasia (the same process by a different name) disappeared within 18 months after successful kidney transplantation restored normal urine flow through the bladder.¹⁴

These observations suggest that eliminating the chronic irritant, whether it is infection, catheter use, immunosuppressive medication, or a defunctionalized bladder, can allow the lesion to regress without surgical intervention. In practice, though, most lesions are resected at the time of discovery because a tissue diagnosis is needed to rule out malignancy.

Recurrence and Long-Term Outlook

Although nephrogenic adenoma is benign and does not transform into cancer, it does recur at a surprisingly high rate. In a long-term follow-up study with a median observation period of about three years, 63% of patients developed at least one recurrence. Of those recurrences, the majority were more nephrogenic adenoma, though three patients developed nonspecific cystitis and three developed urothelial carcinoma. The patients who developed cancer, however, already had a prior history of bladder cancer, which makes it difficult to attribute the cancer to the nephrogenic adenoma itself. The strongest independent predictor of recurrence was a history of prior transurethral bladder tumor resection.¹⁵

This high recurrence rate does not mean the lesion is aggressive. It more likely reflects the persistence of the underlying inflammatory conditions that caused it in the first place. If someone continues to use intermittent catheterization or has ongoing urinary infections, the environment that fostered the original growth remains. Recurrence after resection tends to be managed the same way as the initial lesion: repeat cystoscopy with biopsy and, if confirmed, transurethral resection.

The practical implication is that patients diagnosed with nephrogenic adenoma should expect periodic cystoscopic surveillance. This is especially true for patients with a coexisting history of bladder cancer, where the overlap in symptoms and cystoscopic appearance makes it important to catch any new urothelial lesion early. Two of the patients who developed urothelial carcinoma recurrences in the study above ultimately required radical cystectomy and urinary diversion, a far more serious surgery, underscoring the importance of continued monitoring.¹⁵

Nephrogenic Adenoma in Augmented Bladders

A specific population where nephrogenic adenoma deserves extra attention is patients who have undergone bladder augmentation, a surgical procedure in which a segment of bowel is used to enlarge a small or poorly functioning bladder. This is most common in people with congenital conditions like spina bifida (myelodysplasia), sacral agenesis, or bladder exstrophy. In a review of ten such patients, the underlying conditions were myelodysplasia in seven, sacral agenesis in two, and bladder exstrophy in one. The average time from augmentation surgery to discovery of nephrogenic adenoma was about nine years.¹⁶

Augmented bladders are at particularly high risk for several reasons. These patients almost always perform intermittent catheterization, which provides ongoing mechanical trauma to the bladder lining. The interface between native bladder tissue and transplanted bowel creates an area of chronic low-grade inflammation. And many of these patients have recurrent urinary infections. Lesions in the augmented bladder were found along the floor, near catheterization channel entrances, and adjacent to the bowel-bladder junction, all sites of maximal irritation.¹⁶

For patients with augmented bladders who are already on a schedule of periodic endoscopic surveillance (which many are, because augmented bladders carry an independently increased risk of bladder cancer), awareness of nephrogenic adenoma prevents unnecessary alarm and overtreatment. A biopsy that comes back as nephrogenic adenoma in this setting is generally reassuring, but ongoing surveillance remains warranted both for recurrence of the adenoma and for the separate baseline cancer risk associated with the augmentation itself.

Common Misconceptions

The biggest misconception about nephrogenic adenoma is that “adenoma” implies pre-cancer. In other organs, adenomas can be precancerous: colon polyps, for instance, are adenomas that sometimes progress to colon cancer. Nephrogenic adenoma does not follow this pattern. There is no established pathway from nephrogenic adenoma to carcinoma. Patients who develop cancer after a nephrogenic adenoma diagnosis almost invariably had an independent cancer history already.

Another persistent misunderstanding involves the AMACR staining pattern. AMACR is sometimes associated in clinical parlance with prostate cancer, where it serves as a diagnostic marker. When pathologists see AMACR positivity in a bladder biopsy, there can be a reflexive concern about malignancy. But as noted earlier, more than half of nephrogenic adenomas express AMACR.⁷ AMACR positivity in the context of a bladder lesion that is also PAX2/PAX8 positive and p63/GATA3 negative does not indicate cancer; it points toward nephrogenic adenoma. The staining panel needs to be read as a whole, not one marker at a time.

Finally, the term “nephrogenic metaplasia,” which you may see in older literature referring to the same condition, sometimes leads patients to worry about metaplasia as a concept. In other contexts, certain types of metaplasia (like Barrett’s esophagus) do carry a cancer risk. But nephrogenic metaplasia of the bladder is not one of them. The renaming to “nephrogenic adenoma” in modern pathology reports has helped reduce this confusion somewhat, though the two terms still coexist in clinical practice.

When Lesions Show Up Outside the Bladder

While the bladder accounts for the vast majority of nephrogenic adenomas, the lesion can appear anywhere along the urothelium-lined urinary tract. The prostatic urethra is a particularly tricky location because it introduces the possibility of confusion with prostatic adenocarcinoma, a far more common and clinically significant cancer. A nephrogenic adenoma in the prostatic urethra may be encountered during a transurethral prostate procedure and, if not recognized, can lead to misdiagnosis.⁹ The key differentiator is that nephrogenic adenoma does not stain for prostate-specific antigen (PSA), while true prostatic adenocarcinoma does.¹²

Cases in the renal pelvis and ureter are rarer still but present their own diagnostic headaches. A mass in the renal pelvis is typically assumed to be a urothelial carcinoma until proven otherwise, and the biopsy tissue available from these locations is often limited. In these situations, the immunohistochemical profile becomes even more critical. PAX8 positivity and GATA3 negativity in a bland-looking tubular lesion from the renal pelvis should prompt the pathologist to consider nephrogenic adenoma before recommending a major surgical resection for presumed cancer.⁶ Getting this diagnosis right matters enormously, because the difference between nephrogenic adenoma and urothelial carcinoma of the renal pelvis is the difference between surveillance and losing a kidney.

1
PubMed. Derivation of nephrogenic adenomas from renal tubular cells in kidney-transplant recipients
2
PubMed Central. Nephrogenic Adenoma of the Urinary Bladder: A Review of the Literature
3
PubMed Central. Nephrogenic adenoma of the bladder: a single institution experience assessing clinical factors
4
PubMed. Nephrogenic Adenoma: Clinical Features, Management, and Diagnostic Pitfalls
5
PubMed. Nephrogenic adenoma of the urinary tract: A 6-year single center experience
6
PubMed Central. Nephrogenic adenoma of the renal pelvis
7
PubMed. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3
8
PubMed. Computed tomography of nephrogenic adenoma of the urinary bladder
9
PubMed Central. Nephrogenic Adenoma of the Prostatic Urethra Mimicking Prostatic and Bladder Carcinomas
10
PubMed. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison
11
PubMed. Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma
12
The American Journal of Surgical Pathology. Fibromyxoid Nephrogenic Adenoma: A Newly Recognized Variant Mimicking Mucinous Adenocarcinoma
13
PubMed. Nephrogenic adenoma of the bladder after kidney transplantation: spontaneous improvement with azathioprine removal; surgical trauma and cytomegalovirus infection as possible etiologic factors
14
Nephrology Dialysis Transplantation. Nephrogenic metaplasia: long-term haemodialysis and anuria as potential risk factors and reversibility with renal transplantation
15
PubMed Central. Nephrogenic adenoma of the urinary bladder: Clinical features, long-term follow-up and recurrence predictors
16
PubMed. Nephrogenic adenoma in the augmented bladder